RUNX1 is actually a master transcription component that regulates the expression of many genes necessary for hematopoiesis. Studies implied which the RUNX1 - "Our study revealed the important part of your KLF16/MYC regulatory axis in modulating tumor progress and chemotherapy sensitivity in BLCA, suggesting that combining bromodomain inhibitors, such as https://abbv-744anditsimpactongen92468.topbloghub.com/38400823/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers